JOHNSON & JOHNSON (JNJ.DE) Fundamental Analysis & Valuation

FRA:JNJ • US4781601046

Current stock price

204.1 EUR
-3.35 (-1.61%)
Last:

This JNJ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. JNJ.DE Profitability Analysis

1.1 Basic Checks

  • In the past year JNJ was profitable.
  • JNJ had a positive operating cash flow in the past year.
  • Each year in the past 5 years JNJ has been profitable.
  • Each year in the past 5 years JNJ had a positive operating cash flow.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • With an excellent Return On Assets value of 13.46%, JNJ belongs to the best of the industry, outperforming 90.20% of the companies in the same industry.
  • With an excellent Return On Equity value of 32.87%, JNJ belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
  • The Return On Invested Capital of JNJ (14.37%) is better than 76.47% of its industry peers.
  • JNJ had an Average Return On Invested Capital over the past 3 years of 16.34%. This is in line with the industry average of 17.40%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 14.37%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • With an excellent Profit Margin value of 28.46%, JNJ belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
  • JNJ's Profit Margin has improved in the last couple of years.
  • JNJ has a Operating Margin of 27.78%. This is in the better half of the industry: JNJ outperforms 74.51% of its industry peers.
  • JNJ's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 67.92%, JNJ is in line with its industry, outperforming 47.06% of the companies in the same industry.
  • In the last couple of years the Gross Margin of JNJ has remained more or less at the same level.
Industry RankSector Rank
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. JNJ.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so JNJ is still creating some value.
  • The number of shares outstanding for JNJ remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for JNJ has been reduced compared to 5 years ago.
  • JNJ has a worse debt/assets ratio than last year.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.04 indicates that JNJ is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.04, JNJ is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
  • The Debt to FCF ratio of JNJ is 2.43, which is a good value as it means it would take JNJ, 2.43 years of fcf income to pay off all of its debts.
  • JNJ has a Debt to FCF ratio of 2.43. This is in the better half of the industry: JNJ outperforms 74.51% of its industry peers.
  • A Debt/Equity ratio of 0.56 indicates that JNJ is somewhat dependend on debt financing.
  • JNJ's Debt to Equity ratio of 0.56 is in line compared to the rest of the industry. JNJ outperforms 54.90% of its industry peers.
  • Although JNJ's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 5.04
ROIC/WACC1.53
WACC9.37%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • JNJ has a Current Ratio of 1.03. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of JNJ (1.03) is worse than 68.63% of its industry peers.
  • A Quick Ratio of 0.77 indicates that JNJ may have some problems paying its short term obligations.
  • JNJ's Quick ratio of 0.77 is on the low side compared to the rest of the industry. JNJ is outperformed by 70.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

5

3. JNJ.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.11% over the past year.
  • The Earnings Per Share has been growing slightly by 6.11% on average over the past years.
  • JNJ shows a small growth in Revenue. In the last year, the Revenue has grown by 6.05%.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • Based on estimates for the next years, JNJ will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.75% on average per year.
  • Based on estimates for the next years, JNJ will show a small growth in Revenue. The Revenue will grow by 6.02% on average per year.
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y8.75%
Revenue Next Year7.24%
Revenue Next 2Y6.55%
Revenue Next 3Y6.35%
Revenue Next 5Y6.02%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

2

4. JNJ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 22.14 indicates a rather expensive valuation of JNJ.
  • The rest of the industry has a similar Price/Earnings ratio as JNJ.
  • JNJ's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.78.
  • JNJ is valuated rather expensively with a Price/Forward Earnings ratio of 20.51.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JNJ is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.54, JNJ is valued at the same level.
Industry RankSector Rank
PE 22.14
Fwd PE 20.51
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as JNJ.
  • JNJ's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. JNJ is more expensive than 62.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 29.23
EV/EBITDA 17.41
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.8
PEG (5Y)3.63
EPS Next 2Y8.38%
EPS Next 3Y8.73%

5

5. JNJ.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.15%, JNJ has a reasonable but not impressive dividend return.
  • JNJ's Dividend Yield is a higher than the industry average which is at 1.94.
  • Compared to an average S&P500 Dividend Yield of 1.83, JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.15%

5.2 History

  • On average, the dividend of JNJ grows each year by 7.68%, which is quite nice.
Dividend Growth(5Y)7.68%
Div Incr Years7
Div Non Decr Years7
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • JNJ pays out 46.19% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • JNJ's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

JNJ.DE Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

FRA:JNJ (4/10/2026, 7:00:00 PM)

204.1

-3.35 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.61%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap491.60B
Revenue(TTM)94.19B
Net Income(TTM)26.80B
Analysts76.25
Price Target207.36 (1.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.15%
Yearly Dividend4.39
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years7
Div Non Decr Years7
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)3.26%
PT rev (3m)12.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.08%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-0.03%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE 22.14
Fwd PE 20.51
P/S 6.11
P/FCF 29.23
P/OCF 23.47
P/B 7.06
P/tB N/A
EV/EBITDA 17.41
EPS(TTM)9.22
EY4.52%
EPS(NY)9.95
Fwd EY4.88%
FCF(TTM)6.98
FCFY3.42%
OCF(TTM)8.7
OCFY4.26%
SpS33.39
BVpS28.91
TBVpS-6.25
PEG (NY)2.8
PEG (5Y)3.63
Graham Number77.44
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.03%
ROIC 14.37%
ROICexc 16.57%
ROICexgc 67.45%
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
ROICexc(3y)19.6%
ROICexc(5y)18.23%
ROICexgc(3y)74.51%
ROICexgc(5y)73.44%
ROCE(3y)20.24%
ROCE(5y)18.7%
ROICexgc growth 3Y3.9%
ROICexgc growth 5Y-2.01%
ROICexc growth 3Y8.52%
ROICexc growth 5Y5.62%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.36
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 6.81
Cash Conversion 72.86%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 5.04
F-Score4
WACC9.37%
ROIC/WACC1.53
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.24%
Revenue Next 2Y6.55%
Revenue Next 3Y6.35%
Revenue Next 5Y6.02%
EBIT growth 1Y12.82%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.27%
EBIT Next 3Y11.78%
EBIT Next 5Y8.55%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / JNJ.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


How profitable is JOHNSON & JOHNSON (JNJ.DE) stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 7 / 10.


What is the financial health of JOHNSON & JOHNSON (JNJ.DE) stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


Can you provide the expected EPS growth for JNJ stock?

The Earnings per Share (EPS) of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 7.91% in the next year.